BioVentrix’s Revivent TC System Receives 2021 NUB Status 1 Reimbursement Renewal

February 8, 2021—BioVentrix, Inc. announced that InEK, the German Institute for Hospital Remuneration, has renewed the NUB Status 1 reimbursement designation in Germany for the company’s Revivent TC transcatheter ventricular enhancement system used in BioVentrix’s LIVE therapy (less invasive ventricular enhancement).

The company advised that in addition to the standard reimbursement based on the Diagnosis-Related Group of the device, NUB Status 1 allows hospitals to negotiate supplemental reimbursement for LIVE therapy based on its recognition as an innovative medical device with the potential to improve the standard of care for patients.

According to BioVentrix, LIVE therapy uses the Revivent TC system to exclude scar tissue on the left ventricle that has occurred from a heart attack so the healthy portion of the heart can operate more efficiently. Microanchors are implanted and designed to remodel the heart to a more normal shape and size and reduce wall stress, which has been shown to improve blood flow throughout the body.

The Revivent TC system received CE Mark approval in 2016 and is commercially available in Europe. In the United States, BioVentrix is currently enrolling patients in the pivotal ALIVE trial to support regulatory approval of the Revivent TC system.